Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on advanced cancer treatments, has scheduled its Q2 2025 financial results announcement for Wednesday, August 13, 2025, before market opening. The company will also provide business updates during this announcement.
The press release will be accessible through the newsroom section of Perspective's website.
Perspective Therapeutics (NYSE AMERICAN: CATX), un'azienda radiopharmaceutica specializzata in trattamenti avanzati per il cancro, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per mercoledì 13 agosto 2025, prima dell'apertura dei mercati. Durante questo annuncio, la società fornirà anche aggiornamenti sulle attività aziendali.
Il comunicato stampa sarà disponibile nella sezione newsroom del sito web di Perspective.
Perspective Therapeutics (NYSE AMERICAN: CATX), una compañía de radiofármacos enfocada en tratamientos avanzados contra el cáncer, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el miércoles 13 de agosto de 2025, antes de la apertura del mercado. La empresa también ofrecerá actualizaciones comerciales durante este anuncio.
El comunicado de prensa estará disponible en la sección de noticias del sitio web de Perspective.
Perspective Therapeutics (NYSE AMERICAN: CATX)는 첨단 암 치료에 중점을 둔 방사성 의약품 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 13일 수요일 시장 개장 전으로 예정했습니다. 회사는 이 발표에서 사업 현황 업데이트도 제공할 예정입니다.
보도 자료는 Perspective 웹사이트의 뉴스룸 섹션에서 확인할 수 있습니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une société radiopharmaceutique spécialisée dans les traitements avancés du cancer, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 pour le mercredi 13 août 2025, avant l'ouverture des marchés. La société fournira également des mises à jour commerciales lors de cette annonce.
Le communiqué de presse sera accessible dans la section newsroom du site web de Perspective.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein radiopharmazeutisches Unternehmen, das sich auf fortschrittliche Krebstherapien spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Mittwoch, den 13. August 2025, vor Börsenöffnung, terminiert. Das Unternehmen wird während dieser Ankündigung auch geschäftliche Updates geben.
Die Pressemitteilung wird im Newsroom-Bereich der Website von Perspective zugänglich sein.
- None.
- None.
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 before the market opens. The press release will be available on the newsroom section of the Company’s website at https://perspectivetherapeutics.com/newsroom/press-releases.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company’s melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations.
For more information, please visit the Company’s website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company’s ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company’s proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company’s prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company’s belief that its “theranostic” approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company’s ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
When will Perspective Therapeutics (CATX) release Q2 2025 earnings?
Where can I find Perspective Therapeutics (CATX) Q2 2025 earnings release?
What will Perspective Therapeutics (CATX) Q2 2025 earnings announcement include?
What type of company is Perspective Therapeutics (CATX)?
